NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 3.0% and is now trading at $81.64.
View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Friday, July, 31st. The company reported $1.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.14 by $0.23. The company had revenue of $10.87 billion for the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a return on equity of 53.61% and a net margin of 22.20%. The company's revenue for the quarter was down 7.6% on a year-over-year basis. During the same period last year, the business earned $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a yield of 2.99%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its Board of Directors has approved a share repurchase plan on Thursday, October 25th 2018, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 5.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its shares are undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 equities research analysts have issued twelve-month target prices for Merck & Co., Inc.'s stock. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $94.93 in the next year. This suggests a possible upside of 16.3% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Media headlines about MRK stock have been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 14,560,000 shares, a drop of 7.9% from the June 15th total of 15,810,000 shares. Based on an average daily trading volume, of 11,610,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.6% of the shares of the stock are sold short.
View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.50%), Swiss National Bank (0.43%), LSV Asset Management (0.34%), Principal Financial Group Inc. (0.29%), New York State Teachers Retirement System (0.15%) and Robeco Institutional Asset Management B.V. (0.14%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., DAVENPORT & Co LLC, Prudential PLC, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., LSV Asset Management, Strs Ohio, Principal Financial Group Inc., and First Trust Advisors LP.
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $81.64.

Merck & Co., Inc. has a market capitalization of $206.07 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]